ADVENTRX Pharmaceuticals, Inc. — Q2 2011 Form 10-Q
Period: Quarter and six months ended June 30, 2011; unaudited. The filing is for ADVENTRX Pharmaceuticals, Inc., not Savara Inc. The company described itself as a development-stage specialty pharmaceutical business. It reported no product sales and no revenue in either the quarter or first half of 2011.
Financial performance and position
| Metric | Q2 2011 / June 30, 2011 | Comparable 2010 / Dec. 31, 2010 |
|---|---|---|
| Revenue | $0 for the quarter and first half | $0 for the comparable quarter and first half |
| Research and development expense | $1.34 million for Q2; $1.95 million for six months | $0.63 million; $1.87 million |
| Selling, general and administrative expense | $1.82 million for Q2; $3.40 million for six months | $1.30 million; $2.48 million |
| Transaction-related expense | $1.23 million for Q2; $2.03 million for six months | $0 |
| Net loss | $4.39 million for Q2; $7.35 million for six months | $1.92 million; $4.32 million |
| Net loss applicable to common stock / diluted loss per share | $4.39 million / $0.17 for Q2; $7.35 million / $0.30 for six months | $5.04 million / $0.39; $9.96 million / $0.86 |
| Cash and cash equivalents | $41.96 million | $27.98 million at December 31, 2010 |
| Total current assets / current liabilities | $42.73 million / $2.36 million | $28.41 million / $1.80 million |
| Debt | No notes payable or long-term debt reported on the balance sheet | — |
With no current-period revenue, gross margin is not meaningful. Six-month operating cash use was $6.98 million, compared with $5.18 million in 2010. Investing activities used $11,903; financing activities provided $20.96 million, primarily from the January 2011 stock-and-warrant financing. The filing does not provide a clear standalone quarterly cash-flow figure. Management said cash was expected to fund planned operations for at least 12 months from June 30, 2011.
Material changes and key developments
- Q2 R&D expense rose about 112% year over year, mainly from Exelbine research-related manufacturing and increased clinical and consulting work. First-half R&D expense rose about 4%.
- First-half SG&A increased about 37%, reflecting hiring, estimated 2011 bonus expense and Exelbine commercial-readiness work.
- Net loss increased year over year in both Q2 and the first half, while loss applicable to common stock decreased versus 2010 because the 2010 comparisons included noncash deemed dividends from equity financings.
- In January, ADVENTRX raised $22.5 million gross and received $21.0 million net through a registered direct financing. Related warrants could generate up to $11.3 million in additional proceeds, subject to exercise and ownership limitations.
- ADVENTRX completed its SynthRx acquisition on April 8, issuing 2.8 million shares at closing and assuming approximately $0.3 million of SynthRx transaction expenses. Preliminary acquisition purchase price was $6.67 million, including $6.55 million assigned to in-process R&D. Up to 13.48 million additional shares could be issued upon specified ANX-188 development and regulatory milestones.
Outlook, risks and unusual items
- Exelbine (ANX-530): The FDA accepted the NDA for filing and set a September 1, 2011 PDUFA goal date. The company continued launch-preparation work contingent on approval, estimating about $3.0 million of commercialization-related expenses for the rest of 2011 and recurring sales and marketing expense below $10 million annually.
- ANX-514: Following FDA feedback, the company planned a comparative safety study against Taxotere and was developing a protocol. It aimed to be able to start the study in 2012 if it reached agreement with the FDA; it also considered partnering, sale or exclusive licensing and could discontinue development if costs were not justified.
- ANX-188: The company was developing the acquired candidate for pediatric sickle cell crisis and said a Phase 3 trial could begin in 2012 if it reached timely agreement with the FDA on a protocol. Estimated third-party costs through NDA submission were approximately $15 million to $25 million; timing and total costs remained uncertain.
- Acquisition accounting included a $1.4 million contingent-consideration liability and a $0.39 million contingent asset at June 30. Fair-value remeasurement produced a net $0.2 million charge to transaction-related expense during the quarter.
- Key risks include clinical and regulatory delays or failure, commercialization and manufacturing challenges, dependence on third parties and single-source suppliers, potential dilution, and the possibility that additional financing may not be available on acceptable terms. Management’s runway estimate depends on planned spending and could shorten with expanded development, acquisitions or unexpected costs.
- The company reported disclosure controls and procedures were effective as of June 30, 2011, with no material change in internal control identified during the quarter. It reported no specific material legal proceeding in this filing; it noted that ordinary-course claims could arise.
Investor verification priorities
- Confirm the September 1, 2011 FDA review target and any subsequent decision or requirements for Exelbine.
- Track FDA alignment, study design, timing and funding needs for ANX-514 and ANX-188, including the estimated ANX-188 development cost.
- Monitor quarterly cash burn against the stated 12-month runway and assess whether further financing is needed.
- Review potential dilution from outstanding warrants and the SynthRx milestone shares; verify milestone accounting and the contingent-consideration valuation.
- Confirm the filing-company identity: this 10-Q names ADVENTRX Pharmaceuticals, Inc., despite the request metadata naming Savara Inc.